These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

972 related items for PubMed ID: 31427046

  • 21. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
    Silberstein SD, Cohen JM, Yang R, Gandhi SK, Du E, Jann AE, Marmura MJ.
    J Headache Pain; 2021 Jan 07; 22(1):2. PubMed ID: 33413075
    [Abstract] [Full Text] [Related]

  • 22. Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
    Brandes JL, Kudrow D, Yeung PP, Sakai F, Aycardi E, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y.
    Cephalalgia; 2020 Apr 07; 40(5):470-477. PubMed ID: 31752521
    [Abstract] [Full Text] [Related]

  • 23. Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine.
    Winner PK, Spierings ELH, Yeung PP, Aycardi E, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y.
    Headache; 2019 Nov 07; 59(10):1743-1752. PubMed ID: 31675102
    [Abstract] [Full Text] [Related]

  • 24. The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.
    Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME.
    Headache; 2019 Mar 07; 59(3):383-393. PubMed ID: 30450545
    [Abstract] [Full Text] [Related]

  • 25. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
    Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS.
    Lancet Neurol; 2014 Sep 07; 13(9):885-92. PubMed ID: 25127173
    [Abstract] [Full Text] [Related]

  • 26. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
    Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD.
    Lancet Neurol; 2015 Nov 07; 14(11):1091-100. PubMed ID: 26432181
    [Abstract] [Full Text] [Related]

  • 27. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.
    Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, Bigal ME.
    Headache; 2017 Oct 07; 57(9):1375-1384. PubMed ID: 28862758
    [Abstract] [Full Text] [Related]

  • 28. Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study.
    Sakai F, Suzuki N, Ning X, Ishida M, Usuki C, Iba K, Isogai Y, Koga N.
    Drug Saf; 2021 Dec 07; 44(12):1355-1364. PubMed ID: 34687446
    [Abstract] [Full Text] [Related]

  • 29. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
    Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A.
    Lancet Neurol; 2020 Sep 07; 19(9):727-737. PubMed ID: 32822633
    [Abstract] [Full Text] [Related]

  • 30. Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
    Diener HC, McAllister P, Jürgens TP, Kessler Y, Ning X, Cohen JM, Campos VR, Barash S, Silberstein SD.
    Cephalalgia; 2022 Jul 07; 42(8):769-780. PubMed ID: 35331009
    [Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
    Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B.
    Lancet Neurol; 2022 Jul 07; 21(7):597-607. PubMed ID: 35716692
    [Abstract] [Full Text] [Related]

  • 32. No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study.
    Blumenfeld AM, Stevanovic DM, Ortega M, Cohen JM, Seminerio MJ, Yang R, Jiang B, Tepper SJ.
    Headache; 2020 Nov 07; 60(10):2431-2443. PubMed ID: 33009665
    [Abstract] [Full Text] [Related]

  • 33. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials.
    Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW.
    Cephalalgia; 2019 Jan 07; 39(1):52-60. PubMed ID: 29722276
    [Abstract] [Full Text] [Related]

  • 34. Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
    Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC.
    Headache; 2021 Oct 07; 61(9):1376-1386. PubMed ID: 34374086
    [Abstract] [Full Text] [Related]

  • 35. Effects of fremanezumab on migraine-associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double-blind, placebo-controlled trial.
    Tatsumoto M, Ishida M, Iba K, Kim BK, Ning X, Osawa C, Nakai M, Kurita Y.
    Headache; 2024 Sep 02. PubMed ID: 39221611
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.
    Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, Dodick DW.
    Neurology; 2020 Nov 03; 95(18):e2487-e2499. PubMed ID: 32913018
    [Abstract] [Full Text] [Related]

  • 38. Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.
    Lipton RB, Cohen JM, Bibeau K, Galic M, Seminerio MJ, Ramirez Campos V, Halker Singh RB, Ailani J.
    Headache; 2020 Nov 03; 60(10):2444-2453. PubMed ID: 33179323
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Fremanezumab for the preventive treatment of migraine.
    Silberstein SD, Cohen JM, Yeung PP.
    Expert Opin Biol Ther; 2019 Aug 03; 19(8):763-771. PubMed ID: 31177856
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 49.